We hypothesized that due to its effect on BRCA1 phosphorylation and HR activity, pharmacological ATR inhibition could sensitize rhabdomyosarcoma cells to PARP1 inhibition. The gene discussed is ATR; the disease is rhabdomyosarcoma.